Notice of Closed Meeting, 77467 [2020-26558]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices
77467
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, SETTINGS)—Continued
PICOTS element
Inclusion criteria
Outcomes ................
All KQs: Primary efficacy outcomes (i.e., pain, function, disability, pain interference); harms and adverse effects
(e.g., dizziness, nausea, sedation, development of cannabis use disorder); secondary outcomes (i.e., psychological distress including depression and anxiety, quality
of life, opioid use, sleep quality, sleep disturbance, health
care utilization).
All KQs: short term (1 to <6 months), intermediate term (6
to <12 months), long term (≥1 year).
All KQs: Any nonhospital setting or setting of self-directed
care.
All KQs: RCTs; observational studies with a concurrent
control group for harms, and to fill gaps in the evidence
for benefits.
Time of follow-up .....
Setting .....................
Study design ............
Exclusion criteria
All KQs: Other outcomes.
All KQs: studies with <1-month of treatment or followup
after treatment.
All KQs: Hospital care, hospice care, emergency department care.
All KQs: Other study designs.
Abbreviations: RCT = randomized controlled trial.
Dated: November 27, 2020.
Marquita Cullom,
Associate Director.
[FR Doc. 2020–26570 Filed 12–1–20; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)RFA–PS–21–003, PrEP Choice:
Increasing the Use of HIV Pre-exposure
Prophylaxis in an Era of Choices; and
RFA–PS–21–004, Implementing and
Evaluating a Data-to-Care Rx Strategy.
Date: February 23–24, 2021.
Time: 10:00 a.m.–5:00 p.m., EST.
Place: Teleconference, Centers for
Disease Control and Prevention, Room
VerDate Sep<11>2014
17:39 Dec 01, 2020
Jkt 253001
1080, 8 Corporate Square Boulevard,
Atlanta, Georgia 30329–4027.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE, Mailstop US8–1,
Atlanta, Georgia 30329–4027, (404) 718–
8833, GAnderson@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–26558 Filed 12–1–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0121]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. The meeting will be webcast live
via the World Wide Web.
DATES: The meeting will be held on
December 1, 2020 from 2:00 p.m. to 5:00
p.m., EST (times subject to change).
Written comments must be received
on or before December 3, 2020.
ADDRESSES: For more information on
ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/
index.html.
You may submit comments, identified
by Docket No. CDC–2020–0121 by any
of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Docket No. CDC–2020–0121,
c/o Attn: November 23, 2020 ACIP
Meeting, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, GA 30329–4027.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 41 CFR 102–3.150(b),
less than 15 calendar days’ notice is
E:\FR\FM\02DEN1.SGM
02DEN1
]]>Agencies
[Federal Register Volume 85, Number 232 (Wednesday, December 2, 2020)]
[Notices]
[Page 77467]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26558]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)- RFA-PS-21-003, PrEP Choice:
Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of
Choices; and RFA-PS-21-004, Implementing and Evaluating a Data-to-Care
Rx Strategy.
Date: February 23-24, 2021.
Time: 10:00 a.m.-5:00 p.m., EST.
Place: Teleconference, Centers for Disease Control and Prevention,
Room 1080, 8 Corporate Square Boulevard, Atlanta, Georgia 30329-4027.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop US8-1,
Atlanta, Georgia 30329-4027, (404) 718-8833, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-26558 Filed 12-1-20; 8:45 am]
BILLING CODE 4163-18-P
